Merck & Co starts phase IIb study of tulisokibart in rheumatoid arthritis
The study is one of three to start, along with those in hidradenitis suppurativa and radiographic axial spondyloarthritis.
List view / Grid view
The study is one of three to start, along with those in hidradenitis suppurativa and radiographic axial spondyloarthritis.
Here, Jason Fontenot, Chief Scientific Officer of Sangamo Therapeutics, discusses with EPR’s Hannah Balfour how the industry is developing chimeric antigen receptor (CAR) T regulatory cells (Tregs) as a potentially paradigm-shifting therapeutic option for conditions driven by the immune system, such as autoimmunity and transplant rejection.
In a new paper, Lumen Bioscience detailed how spirulina can be genetically engineered for to rapidly produce large quantities of biologic drugs.
A novel flow synthesis method using recoverable solvents will be used to supply NEt-3IB, an inflammatory bowel disease (IBD) drug candidate.
The microbial content of the gut has a well established role in health and disease. In this article, European Pharmaceutical Review’s Hannah Balfour explores the development and formulation of live biotherapeutic products (LBPs), an emerging treatment modality that seeks to capitalise on the interaction between the microbiota and host in…
An innovative new pill can deliver large quantities of monoclonal antibodies and other drugs into the stomach lining after swallowing.
Janssen has released abstracts for four studies evaluating Stelara® (ustekinumab) in Crohn's disease (CD) and ulcerative colitis (UC).
Nanoparticles offer a promising alternative to conventional drug delivery that allow for more precise targeting and controlled release. Here, Dr Fabrice Navarro discusses the benefits of these nanocarriers and their potential as a therapy for inflammatory bowel diseases (IBDs).
YuflymaTM (CT-P17) has been approved for the treatment of thirteen chronic inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and psoriatic arthritis, in Europe.
Cannabinoids, their potential therapeutic uses and the research needed for medical cannabis were the topics of discussion at the ‘Medical cannabis: what UK doctors need to know’ event held last week.
The use of certain diabetes drugs, known as dipeptidyl peptidase-4 inhibitors, are associated with an increased risk of inflammatory bowel disease...
Researchers have developed a biosensor that can detect diseased exosomes, important indicators of various health conditions...
The findings from the two pivotal phase 3 trials pave the way for ozanimod to enter the New Drug Approval process with the FDA...
28 October 2016 | By Dolomite Bio
Dolomite Bio’s Single Cell RNA-Seq System is helping researchers at the University of Helsinki to investigate autoimmune diseases. Focusing on gastrointestinal conditions – such as coeliac disease and inflammatory bowel disease – the Molecular Genetics of Immunological Diseases group is using the system to study T-cell activation and response at…
13 July 2016 | By Victoria White, Digital Content Producer
Collaborating with Marvel Custom Solutions, Takeda’s IBD Unmasked initiative features an IBD Super Hero, Samarium, and a graphic novel series...